- May 21, 2013
- 09:02 PM CET
- search
- T&C's
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2013 EVOTEC
- Loading...
Archive
Evotec and Harvard University to collaborate on development of new class of antibacterials
*TARGET PGB (PEPTIDOGLYCAN BIOSYNTHESIS) IS THE FOCUS OF COLLABORATION
DESIGNED TO DEVELOP NOVEL FAMILY OF ANTIBACTERIAL DRUGS BASED ON HIGHLY
VALIDATED TARGET
Hamburg, Germany and Cambridge, MA - 16 May 2013: Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing
novel anti-bacterial agents based on a highly validated target family
involved in bacterial cell wall biosynthesis.
Evotec Q1 2013: Driving Innovation Efficiency
- STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION
EFFICIENCY
- EVOTEC'S DRUG DISCOVERY PLATFORM GENERATES GROWTH
- NEW HORMONE IDENTIFIED AS PART OF THE CUREBETA INITIATIVE
- GUIDANCE 2013 CONFIRMED
Hamburg, Germany - 14 May 2013: Evotec AG today reported financial results and corporate updates for the first quarter of 2013.
- read moreDana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology
Hamburg, Germany and Boston, MA - 30 April 2013: The Belfer Institute for
Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG
today announced a research collaboration aimed at discovering and commercialising novel
cancer treatments based on epigenetic drug mechanisms.
Evotec expands compound management capability to East Coast of the United States
Hamburg, Germany - 29 April 2013: Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand
the offering of its Compound Management Services on the East Coast of the
United States.
New hormone to treat diabetes published in 'Cell'
Hamburg, Germany, 26 April 2013: Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone 'betatrophin' that controls beta cell proliferation as potential diabetes treatment.
- read moreEvotec extends drug discovery alliance with Genentech
Hamburg, Germany - 22 April 2013: Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years.
- read moreForward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress
Hamburg, Germany - 26 March 2013: Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012.
- read moreCorporate Update
Hamburg, Germany - 18 March 2013: Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.
Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.
Hamburg, Germany - 11 January 2013: Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone.